225 related articles for article (PubMed ID: 29038266)
1. Potency of Meropenem-Vaborbactam in Lung Surfactant.
Rubio-Aparicio D; Loutit J; Dudley M; Lomovskaya O
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038266
[TBL] [Abstract][Full Text] [Related]
2. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
3.
Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
[TBL] [Abstract][Full Text] [Related]
6. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
Castanheira M; Rhomberg PR; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
[TBL] [Abstract][Full Text] [Related]
7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
[TBL] [Abstract][Full Text] [Related]
10. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
11. Biochemical Activity of Vaborbactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712199
[TBL] [Abstract][Full Text] [Related]
12. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Patel TS; Pogue JM; Mills JP; Kaye KS
Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
[TBL] [Abstract][Full Text] [Related]
14. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
15. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
16. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
18. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
19. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.
Munson E; Huband MD; Castanheira M; Fedler KA; Flamm RK
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):324-328. PubMed ID: 29276104
[TBL] [Abstract][Full Text] [Related]
20. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]